Depression... disturbed sleep...

Sinequan
brand of doxepin
* Trade Mark
lifts depression...
promotes restful sleep

- SEDATIVE ANTIDEPRESSANT
- ONCE NIGHTLY DOSAGE

Indications: depression with or without anxiety. Contraindications: glaucoma, urinary retention, hypersensitivity to the drug. Side effects: dry mouth and drowsiness are most commonly reported. Precautions: Sinequan may potentiate other compounds – e.g. monoamine oxidase inhibitors; not recommended in pregnancy or children under 12 years age. Dosages: range 50 mg to 300 mg daily in divided doses, up to 100 mg may be given as a single dose at night. Packs and Basic N.H.S. Cost: 10 mg capsules (PL 57/5032), pack of 100, £2.96; 25 mg capsules (PL 57/5033), pack of 100, £4.24; 50 mg capsules (PL 57/5034), pack of 100, £7.01; 75 mg capsules (PL 57/0131), pack of 60, £5.64.

Full information on request to the Company.

Pfizer
PFIZER LIMITED
SANDWICH, KENT
JOURNAL OF MENTAL DEFICIENCY RESEARCH

Editor: Dr B W Richards

THE JOURNAL OF MENTAL DEFICIENCY RESEARCH contains original research on medical and psychological problems relevant to mental subnormality.

Recent articles include:

The Effect of Treatment on Mental and Psychomotor Development of Marasmic Infants according to Age of Admission. J. M. Celedon, Diane Csaszar, Jennifer Middleton and Isidora de Andracca.


Preferences in Attention to Visual Cues in Down Syndrome and Normal Children. B. Stratford.

Dental Asymmetry and Mental Retardation: A Comparison of Subjects with Mental Retardation Resulting from Prenatal or Postnatal Influences. H. S. Barden

Follow-up of Case of Advanced Survival and Trisomy 18. Arabella Smith and Gesina M. den Dulk.

A New Approach to the Treatment of Phenylketonuria. O. E. Pratt.

Extra Dicentric 15pter→q21|22 Chromosomes in Five Unrelated Patients with a Distinct Syndrome of Progressive Psychomotor Retardation, Seizures, Hyper-reactivity and Dermatoglyphic Abnormalities. Maria Zannotti, A. Preto, Paola Rossi Giorvanardi and B. Dallapiccola.

Published quarterly by
THE NATIONAL SOCIETY FOR MENTALLY HANDICAPPED CHILDREN AND ADULTS
123 Golden Lane, London EC1Y 0RT
Yearly Subscription £20.00 U.S.A. $60.00
Important news

Neuroradiology
Edmund H. Burrows and Norman E. Leeds
Two volumes 1184 pages approx
1573 illustrations hardback £65.00 approx
ISBN 0 443 08016 X
A superb, fully comprehensive, completely up-to-date guide to the radiology of the brain and spinal cord. Covers the most recently developed investigative techniques, with the emphasis on non-invasive methods. The second volume comprises a unique collection of self-testing exercises, half of which cover specific problems of neuroradiology, while the other half cover many different aspects of the subject.

Neuropeptides
BIOCHEMICAL AND PHYSIOLOGICAL STUDIES
Edited by R. P. Millar
396 pages 4 half-tone + 164 line illustrations hardback £20.00 ISBN 0 443 02265 8
Key papers on rapidly developing areas of knowledge on neuropeptides, written by 23 leading researchers in the UK, USA, Europe and South Africa.

Current Surgical Management of Neurologic Disease
Charles B. Wilson and Julian T. Hoff
368 pages 79 illustrations 494 references hardback £22.00 ISBN 0 443 08042 2
Covers the most recent developments in neurosurgery, in succinct, authoritative terms, with each chapter detailing a specific neurological disorder and its management.

Electrodiagnosis in Clinical Neurology
Edited by Michael J. Aminoff
608 pages 270 illustrations hardback £24.00 ISBN 0 443 08021 6
A comprehensive account of the clinical applications of the electrophysiological methods of investigating the central and peripheral nervous systems.

Disorders of Voluntary Muscle
Edited by Sir John Walton
Fourth edition 1024 pages approx 306 half-tone + 71 line illustrations hardback £48.00 approx ISBN 0 443 01847 2
The latest edition of the most comprehensive and authoritative reference book available on the subject of neuromuscular disease. Contributors provide the most up-to-date research and clinical data available from centres in the USA, UK, Belgium, Sweden, Israel and Australia.

Neonatal Neurology
Gerald M. Fenichel
284 pages 33 half-tone + 48 line illustrations 912 references hardback £14.00 ISBN 0 443 08052 6
A highly practical guide to the diagnosis, treatment and management of neurological disorders in the newborn. The emphasis is on those conditions which either produce symptoms or which must be treated within the first 30 days of life.

Major journal of interest
Neuropeptides
Edited by M. J. Brownstein and John Hughes
This journal aims at rapid publication of papers in this competitive new field. The distinguished Editorial Board will maintain the high standards already established for the journal. Published monthly Annual Subscription £70.00 /$160.00 ISSN 0143-4179

Churchill Livingstone publications should be available from all leading medical booksellers, or in case of difficulty, direct from the publishers. (Please enclose your payment with your order.)

Churchill Livingstone
Robert Stevenson House, 1-3 Baxter’s Place, Leith Walk, Edinburgh EH1 3AF, U.K.
The combination of simple language and straightforward line drawings has made the

ABC OF OPHTHALMOLOGY

one of the most popular series of articles in the Medical Practice section of the British Medical Journal.

All the common problems are covered - visual defects, squints, glaucoma and cataracts - together with detailed instruction on examination, diagnosis and management.

The articles have now been collected into book form - in exactly the same format as they appeared in the BMJ - price: Inland £2.50; Overseas US$6.25 (Inland £2.00; Overseas US$5.00 for BMA members).

Order your copy now
From: The Publisher, British Medical Journal, BMA House, Tavistock Square, London WC1H 9JR or any leading bookseller
Presentation
Madopar contains a combination of levodopa and the decarboxylase inhibitor benzerazide in the ratio of 4:1. Madopar 62.5 capsules contain 50mg levodopa and 12.5mg benzerazide hydrochloride (equivalent to 13.75mg of the base). Madopar 125 capsules contain 100mg levodopa and 25mg benzerazide hydrochloride (equivalent to 31.25mg of the base). Madopar 250 capsules contain 200mg levodopa and 50mg benzerazide hydrochloride (equivalent to 93.75mg of the base).

Indications
Parkinsonism - diopatic, postencephalitic.

Dosage
Dosage is variable and the data sheet should be consulted for full details. The effective daily dose usually lies between four and eight capsules of Madopar 125 (two to four capsules of Madopar 250) daily in divided doses. Most patients require no more than six capsules of Madopar 125 daily. In severe or resistant cases, the initial treatment with the capsule of Madopar 62.5 can be increased to twice daily, increasing by one capsule every third or fourth day may suffice.

Contra-indications
Narrow-angle glaucoma, oesophageal stricture, peptic ulceration, ulcerative colitis, asthma, diabetes mellitus. Not to be given in conjunction with monoamine oxidase inhibitors or within two weeks of their withdrawal. To patients under 25 years of age, to pregnant women, or to patients who have a history of, or who may be suffering from, a malignant melanoma.

Precautions
Drugs which interfere with cardiac function or patients should be advised to seek medical advice. Endocrine, renal, pulmonary, or cardiovascular disease, hepatic disorder, peptic ulceration, osteoporosis, sympathomimetic drugs, antihypertensive drugs. Patients who improve on Madopar therapy should be advised to resume normal activities gradually as height mobilisation may increase the risk of injury.

Side-effects
Nausea and vomiting, gastrointestinal disturbances, psychiatric disturbances, involuntary movements.

Packings
Madopar 62.5 capsules, Madopar 125 capsules, and Madopar 250 capsules in packings of 100.

Licence Numbers
0031 00725 (Madopar 62.5 capsules), 0031 00773 (Madopar 125 capsules), 0031 0074 (Madopar 250 capsules).

Basic NHS Cost
Madopar capsules 62.5 £1.49 per 100
Madopar capsules 125 £1.25 per 100
Madopar capsules 250 £1.50 per 100

References:
1. Neurology, 1976, 26, 359
2. Neurology, 1979, 29, 158

Madopar levodopa plus benzerazide
balanced for optimal performance in Parkinson's disease
62.5, 125 and 250

Mozart, in his Clarinet Quintet, achieved harmony with a balance of 4 + 1.

Roche, with Madopar, struck the right balance of 4 + 1 with levodopa and the decarboxylase inhibitor benzerazide. Chosen from several ratios as the one giving the best results in clinical practice; this combination has proved its rightness over a decade of clinical experience.

The 4 + 1 preparation of levodopa and benzerazide has recently added another string to its bow. In a comparative trial it was shown to be preferred by patients to a 10 + 1 preparation of levodopa and carbidopa because of its better gastro-intestinal tolerance in the critical first three months of treatment.
Reduced Subscription Rates
for Junior Hospital Doctors
Residents and Interns...

Journal of Neurology,
Neurosurgery & Psychiatry

is available to junior hospital doctors
in all parts of the world for a
maximum of four consecutive years at
REDUCED Annual Subscription Rates.
(Thereafter, or when reaching
consultant status this special offer will
no longer apply.) The following reduced
rates are unchanged for the twelve
issues published in 1981.

Inland £17.00
Overseas US $40.00
(The full rates are: Inland £34.00; Overseas US $83.00)

The opportunity to subscribe to this
journal of international authority and
repute at a substantially reduced
subscription rate is one not to be
missed by junior doctors seeking to
specialise in neurology, neurosurgery
or psychiatry.

Please complete the adjacent order
form and send for your subscription
NOW.

Further order forms can be supplied
on request.

ORDER FORM
BMA Publications
BMA House, Tavistock Square
London WC1H 9JR, England

Please enter my subscription to
JOURNAL OF NEUROLOGY,
NEUROSURGERY &
PSYCHIATRY
☐ United Kingdom and
Irish Republic £17.00
☐ Overseas US $40.00
☐ My remittance for ....................... is enclosed
(Please tick appropriate boxes)

NAME..........................................................
..........................................................
ADDRESS..................................................
..........................................................

To be completed by Consultant
I hereby confirm that the above
mentioned doctor is a member
of the junior hospital staff/resident/intern at ..................
..........................................................

Signed......................................................
NEW Mk. 4 E.C.T. APPARATUS
DUOPULSE, ECTONUSTIM, ECTONUS & ECTRON

ALSO
SOMLEC
ELECTRO SLEEP APPARATUS

Send for full details
ECTRON LTD
Knap Close Letchworth Herts SG6 1AQ England
Telephone LETCHWORTH 2124
Cables ECTRON LETCHWORTH

BRITISH COUNCIL MEDICAL COURSE
HEAD INJURIES
6-18 September 1981 in GLASGOW

The aim of this course is to review current knowledge concerning head injuries. It will be held at the University of Glasgow’s Institute of Neurological Sciences, the head injury centre for the West of Scotland. The Directors of Studies will be Professor B. J. Jennett and Mr G. M. Teasdale of the Department of Neurosurgery. The course is primarily for clinicians concerned with the management of head injuries. Neuropathologists and basic scientists will describe the lesions found in fatal cases, the dynamic pathophysiological processes which follow injury and will review experience with experimental injuries. Methods of clinical assessment, neuroradiological diagnosis including CT scanning, and monitoring methods will be discussed and demonstrated. Treatment will be dealt with by neurosurgeons, anaesthetists and others directly involved. Assessment of prognosis and its value as a method of determining the efficacy of treatment will be described. It will also cover areas such as epidemiological aspects and the analysis of local needs for the provision of a service for head injuries. Discussion and debate will be encouraged and members of the course will be expected to contribute their views and experience. This course is intended for experienced neurosurgeons as well as for anaesthetists and other surgeons who have a major responsibility for the care of patients with head injuries.

There are vacancies for 30 members.
Fee fully inclusive £595.
Applications must be received in London by 15 April 1981.
Further information and application forms may be obtained from local overseas Representatives of The British Council or from the Director, Courses Department, The British Council, 65 Davies Street, London W1Y 2AA. Tel. 01-499 8011.
Presentations
(1) Lilac-coloured enteric coated tablets containing 200mg or 500mg sodium valproate (Epilim 200 enteric coated/Epilim 500 enteric coated).
(2) Red cherry-flavoured syrup containing 200mg sodium valproate per 5ml (Epilim Syrup).

Indications
Epilepsy. In women of childbearing age, Epilim should be used only in severe cases or those resistant to other treatment.

Dosage and Administration
To be taken with or after food; tablets should be swallowed whole.
Adults: Initially 600mg/day in divided doses, increasing by 200mg/day at three-day intervals until control is achieved (maximum dose 2600mg/day).
Children over 20kg: Initially 400mg/day in divided doses, with spaced increases until control is achieved (usually in the range of 20-30mg/kg/day).
Children under 20kg: 20mg/kg/day, with spaced increases until control is achieved, up to a maximum of 50mg/kg/day.

Plasma levels of 200μg/ml should be exceeded only with caution and with monitoring of haematological function.

Contra-indications, Warnings, etc.
There are no absolute contra-indications.

Side-effects: Minor gastric irritation and nausea have been observed in some patients at the start of treatment with uncoated tablets, but this can usually be overcome by using the enteric coated tablet, or relieved by standard medication.

Transient hair loss has occurred in some patients; tremor, occasionally seen at high dosages, may be controlled by reduction of dosage. Oedema has been reported.

Reversible prolongation of bleeding time and thrombocytopenia have been reported, but usually at doses above those recommended.

Spontaneous bruising or bleeding is an indication for withdrawal of medication pending investigation. Patients receiving Epilim should be monitored for platelet function before major surgery.

Liver dysfunction, including hepatic failure resulting in fatalities, has occurred in a few patients whose treatment included Epilim. These incidents occurred during the early months of treatment. Although a causal relationship has not been established, it is recommended that liver function be investigated prior to commencing therapy and monitored at two-monthly intervals thereafter for up to six months. Should liver dysfunction be suspected, immediate withdrawal of the drug is indicated, prior to full investigation of the possible causes. Caution should be exercised when administering Epilim to patients with pre-existing liver disease.

Combined medication: When adding Epilim to existing anticonvulsant medication, e.g. barbiturates, the sedative effects of the latter may be enhanced, and it may therefore be necessary to reduce their dosage. As Epilim may potentiate the effect of mono-amine oxidase inhibitors and other antidepressants, dosage of such compounds should also be reduced.

Diabetic patients: Epilim may cause false
Epilim 200 enteric coated
Following the success of the Epilim 500 enteric coated tablet in improving gastrointestinal tolerance of high dose Epilim treatment, Labaz are pleased to announce the availability of Epilim 200 enteric coated.
This new tablet provides the same advantages in terms of acceptability and means that enteric coated tablets can be prescribed when the dosage requirements both 500mg and 200mg tablets.

For this new improved dosage form your prescription should specify

R Tabs Epilim 200 enteric coated

Women of child-bearing age. Sodium valproate, like certain other antiepileptic drugs, has been shown to be teratogenic in animals, in women of childbearing age, the benefits of these compounds should be weighed against the possible hazard suggested by these findings.

So many patients with epilepsy are controlled by

Labaz
CELLOLITE ® Surgical Sponges

CELLOLITE ® is a white, synthetic, X-Ray detectable sponge designed to overcome all the drawbacks of conventional absorbent materials.

The main characteristics of CELLOLITE ® --- its extreme softness and high degree of conformability, its rapid wicking rate and high absorbency capacity, its overall X-Ray opacity and fibre-free nature, all serve to ensure that CELLOLITE ® is the only really safe and efficient sponge for Neurosurgery.

In short, no other material can match the properties of CELLOLITE ®

Why struggle on using the same old fibrous pattie when you can take a giant step forward with CELLOLITE ®? In these days of Space Age surgical techniques why 'make do' with conventional patties?

Use CELLOLITE ® Surgical Sponges, the product born out of Space Age technology, and benefit from the superior properties of a sponge with the needs of the Twenty-first Century in mind.

Benefit from the softness and non-abrasive character, the overall X-Ray opacity possible due to 'state of the art' encapsulation of Barium Sulphate particles chemically bonded to the sponge, and, so important in delicate surgery, the fibre-free nature of CELLOLITE ® which guarantees that no fibres can be shed into the wound, virtually eliminating the risk of granulomas etc. which are a hazard when using conventional patties.

What other product can offer so much?

Use CELLOLITE ® the ideal Neurosurgical Sponge.

Service to Hospitals

Smith & Nephew-Southalls Limited
Alum Rock Rd, Birmingham B8 3DY Telephone: 021-327-0204 Telex: 338340

Cellolate surgical sponges are made from *Merocel  

*Trade Mark of Americal Corporation
Disipal has made her a little more responsive to her phenothiazine therapy.

The addition of Disipal to phenothiazine therapy enables optimum therapeutic response to be achieved without unacceptable side effects. Disipal also elevates the patient’s mood, thus relieving the depression so often associated with major tranquilizer therapy.

**Drug of choice**
Following a three month double blind crossover trial, the authors concluded that: "Orphenadrine is the drug of choice in the treatment of drug-induced extrapyramidal reactions and depression."

**Increased response**
Furthermore, the authors postulate that "the introduction of orphenadrine in the treatment of a patient whose response to phenothiazines is not maintained, might well result in further benefit."

For patients on major tranquilizer therapy

**Disipal**

* controls extra-pyramidal reactions
* elevates patient mood.
HOW TO DO IT

Every doctor knows the sinking sensation induced by waiting one's turn for an examination viva and the social anxieties of changing jobs. The misery of first night nerves does not, however, disappear with time: each decade brings new challenges. On these occasions—chairing a committee, giving evidence in court, appearing on television—practical tips can be enormously helpful. The same is true of the many skills not taught in medical school—how to lecture, referee papers, edit, or use a library. All these and many more nuggets of down-to-earth advice have been collected from past issues of the BMJ to form a compendium for the novice—whatever his or her age or seniority.

Price: Inland £4.00;
    Abroad US$10.00
(Concessionary price to BMA members: Inland £3.50;
    Abroad US$8.75.)

When ordering BMA members must quote their membership number or the full price will be applicable.)

Payment must be enclosed with order or a surcharge of 50p will be made for rendering invoices and statements.

Order your copy now
From: The Publisher
British Medical Journal
BMA House
Tavistock Square
London WC1H 9JR
or any leading bookseller
Neurosurgeon

A 450 bed general hospital is accepting applications for a neurosurgeon. We will also welcome applications for a neurosurgical team.

Applications and nominations should be forwarded immediately to:
Dr. R. A. Haliburton,
Chairman, Search Committee,
Hotel-Dieu Hospital,
1030 Ouellette Avenue,
Windsor, Ontario N9A 1E1
Canada.

The Neurophysiology of the Cerebral Cortex

Lynn Bindman and
Olof C. J. Lippold

This text offers students of physiology an account of the present state of knowledge of the cerebral cortex in more detail than in most textbooks on the central nervous system.

£47.50 boards 512 pages
241 illustrations

Drugs and Disease

The Proceedings of a Symposium organized by the Royal College of Pathologists

Edited by Sheila Worledge

Price: Inland £3.00
Abroad US $7.50
including postage

The Publishing Manager,
JOURNAL OF CLINICAL PATHOLOGY,
BMA House, Tavistock Square,
London WC1H 9JR

Smooth Muscle
An Assessment of Current Knowledge

Edited by Edith Bülbbring,
Alison F. Brading, Allan W. Jones
and Tadao Tomita with 17 contributors

No other single volume at present available contains such expert assessments of the developments and achievements in smooth muscle physiology, anatomy and pharmacology over the last ten years.

£45 boards 576 pages 194 illustrations
Publication 19 March

Edward Arnold

41 Bedford Square,
London WC1B 3D

Published by British Medical Association, Tavistock Square, London WC1H 9JR, and printed in England by Bradleys, Reading & London